Arcutis former officer proposes $1.99M share sale

Three sales during the prior three months are listed, with two reported on September 16, 2026.

Rhea-AI Filing Summary

At Arcutis Biotherapeutics, Inc., former officer Larry Todd Edwards reported a proposed sale of 60,376 common shares through Merrill Lynch, with an aggregate market value of $1,992,408 and an approximate sale date of October 20, 2026. The notice also lists sales during the prior three months: 4,730 shares for $123,834.71 on August 17, 2026, and 50,292 shares for $1,257,300 plus 291,688 shares for $8,298,524 on September 16, 2026.

Key Figures

Proposed sale: 60,376 common shares Aggregate market value: $1,992,408 Prior sale: 4,730 shares; $123,834.71 +2 more

5 metrics

Proposed sale 60,376 common shares Approximate sale date October 20, 2026

Aggregate market value $1,992,408 Proposed sale

Prior sale 4,730 shares; $123,834.71 August 17, 2026

Prior sale 50,292 shares; $1,257,300 September 16, 2026

Prior sale 291,688 shares; $8,298,524 September 16, 2026

Key Terms

Rule 144, Employee Stock Purchase, Restricted Stock Vesting

3 terms

Rule 144 regulatory

"sales are required by paragraph (e) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Employee Stock Purchase financial

"Employee Stock Purchase"

Restricted Stock Vesting financial

"Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ARQT shares did Larry Todd Edwards propose to sell?

Larry Todd Edwards, a former officer, reported a proposed sale of 60,376 common shares through Merrill Lynch, with an aggregate market value of $1,992,408 and an approximate sale date of October 20, 2026.

What prior ARQT share sales did Larry Todd Edwards report?

The listed sales during the prior three months were 4,730 shares valued at $123,834.71 on August 17, 2026, and 50,292 shares valued at $1,257,300 plus 291,688 shares valued at $8,298,524 on September 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/20/2026 - 04:53 PM EDT Accepted by SEC EDGAR 10/20/2026 - 04:53 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001994805
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns Gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Larry Todd Edwards
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	60376	1992408	125691961	10/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/30/2024	Employee Stock Purchase	Arcutis Biotherapeutics			1093	11/30/2024	Cash
Common	05/31/2025	Employee Stock Purchase	Arcutis Biotherapeutics			724	05/31/2025	Cash
Common	11/30/2025	Employee Stock Purchase	Arcutis Biotherapeutics			724	11/30/2025	Cash
Common	05/31/2026	Employee Stock Purchase	Arcutis Biotherapeutics			448	05/31/2026	Cash
Common	03/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			13750	03/01/2026	NA
Common	02/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			4948	02/01/2026	NA
Common	10/01/2025	Restricted Stock Vesting	Arcutis Biotherapeutics			10496	10/01/2025	NA
Common	05/16/2025	Restricted Stock Vesting	Arcutis Biotherapeutics			22549	05/16/2025	NA
Common	02/01/2025	Restricted Stock Vesting	Arcutis Biotherapeutics			3592	02/01/2025	NA
Common	05/16/2024	Restricted Stock Vesting	Arcutis Biotherapeutics			2052	05/16/2024	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Larry Todd Edwards 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	08/17/2026	4730	123834.71
Larry Todd Edwards 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	09/16/2026	50292	1257300
Larry Todd Edwards 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	09/16/2026	291688	8298524

144: Remarks and Signature

Remarks
Date of Notice	10/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Larry Todd Edwards
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)